Rakovina Therapeutics Inc.
RKV.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 391.50K | 877.10K | 853.40K | 464.50K | 195.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.19M | 2.04M | 1.47M | 996.40K | 691.50K |
| Operating Income | -1.19M | -2.04M | -1.47M | -996.40K | -691.50K |
| Income Before Tax | -1.29M | -2.11M | -1.52M | -1.06M | -741.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.29M | -2.11M | -1.52M | -1.06M | -741.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.29M | -2.11M | -1.52M | -1.06M | -741.40K |
| EBIT | -1.19M | -2.04M | -1.47M | -996.40K | -691.50K |
| EBITDA | -1.09M | -1.95M | -1.38M | -899.90K | -592.40K |
| EPS Basic | -0.06 | -0.13 | -0.11 | -0.11 | -0.08 |
| Normalized Basic EPS | -0.04 | -0.08 | -0.07 | -0.07 | -0.05 |
| EPS Diluted | -0.06 | -0.13 | -0.14 | -0.13 | -0.08 |
| Normalized Diluted EPS | -0.04 | -0.08 | -0.07 | -0.07 | -0.05 |
| Average Basic Shares Outstanding | 21.15M | 15.91M | 14.08M | 10.02M | 8.97M |
| Average Diluted Shares Outstanding | 21.15M | 15.91M | 14.08M | 10.02M | 8.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |